Latest / Decera Clinical Education Oncology Podcast
Homologous Recombination Repair (HRR) Testing and Targeted Therapy in Prostate Cancer
In this episode, Colin C. Pritchard, MD, PhD, a pathologist, and Heather H. Cheng, MD, PhD, a medical oncologist, discuss optimal biomarker testing to guide treatment decisions in advanced prostate cancer, with topics including:
Rationale for targeting PARP in prostate cancer with ARI combinations
Study design nuances and findings from key randomized phase III clinical trials evaluating combination therapy with a PARP inhibitor and ARI, including PROpel, MAGNITUDE, and TALAPRO-2
FDA approvals of combination therapy with a PARP inhibitor and ARI, including a comparison of populations based on…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.